April 25, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today top-line results of an abuse liability study with REMOXY®, an investigational drug for the treatment of pain. In the study, REMOXY met all prospectively defined primary endpoints. Full study results were recently published in Pain Medicine, the Official Journal of the American Academy of Pain Medicine. The principal investigator on this study, Lynn R. Webster, MD, has authored over 100 scientific abstracts and is medical director of Lifetree Clinical Research.